Literature DB >> 34883104

Machine learning for mathematical models of HCV kinetics during antiviral therapy.

Alexander Churkin1, Stephanie Kriss2, Asher Uziel2, Ashish Goyal2, Rami Zakh3, Scott J Cotler2, Ohad Etzion4, Amir Shlomai5, Horacio G Rotstein6, Harel Dahari7, Danny Barash8.   

Abstract

Mathematical models for hepatitis C virus (HCV) dynamics have provided a means for evaluating the antiviral effectiveness of therapy and estimating treatment outcomes such as the time to cure. Recently, a mathematical modeling approach was used in the first proof-of-concept clinical trial assessing in real-time the utility of response-guided therapy with direct-acting antivirals (DAAs) in chronic HCV-infected patients. Several retrospective studies have shown that mathematical modeling of viral kinetics predicts time to cure of less than 12 weeks in the majority of individuals treated with sofosbuvir-based as well as other DAA regimens. A database of these studies was built, and machine learning methods were evaluated for their ability to estimate the time to cure for each patient to facilitate real-time modeling studies. Data from these studies exploring mathematical modeling of HCV kinetics under DAAs in 266 chronic HCV-infected patients were gathered. Different learning methods were applied and trained on part of the dataset ('train' set), to predict time to cure on the untrained part ('test' set). Our results show that this machine learning approach provides a means for establishing an accurate time to cure prediction that will support the implementation of individualized treatment.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Direct-acting antivirals; Hepatitis C virus; Machine learning; Mathematical modeling; Viral dynamics

Mesh:

Substances:

Year:  2021        PMID: 34883104      PMCID: PMC8792269          DOI: 10.1016/j.mbs.2021.108756

Source DB:  PubMed          Journal:  Math Biosci        ISSN: 0025-5564            Impact factor:   2.144


  33 in total

1.  Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design.

Authors:  Ruian Ke; Jessica M Conway; David M Margolis; Alan S Perelson
Journal:  JCI Insight       Date:  2018-10-18

2.  Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration.

Authors:  Swikriti Dasgupta; Michio Imamura; Evan Gorstein; Takashi Nakahara; Masataka Tsuge; Alexander Churkin; David Yardeni; Ohad Etzion; Susan L Uprichard; Danny Barash; Scott J Cotler; Harel Dahari; Kazuaki Chayama
Journal:  J Infect Dis       Date:  2020-09-01       Impact factor: 5.226

3.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

4.  Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics.

Authors:  Vladimir Reinharz; Harel Dahari; Danny Barash
Journal:  Math Biosci       Date:  2018-03-15       Impact factor: 2.144

5.  Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications.

Authors:  D R Gretch; C dela Rosa; R L Carithers; R A Willson; B Williams; L Corey
Journal:  Ann Intern Med       Date:  1995-09-01       Impact factor: 25.391

6.  Viral kinetics of hepatitis C virus RNA in patients with chronic hepatitis C treated with 18 MU of interferon alpha daily.

Authors:  Roel E Sentjens; Christine J Weegink; Marcel G Beld; Michel C Cooreman; Henk W Reesink
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-08       Impact factor: 2.566

7.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

8.  Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Authors:  Eric Lawitz; Fred F Poordad; Phillip S Pang; Robert H Hyland; Xiao Ding; Hongmei Mo; William T Symonds; John G McHutchison; Fernando E Membreno
Journal:  Lancet       Date:  2013-11-05       Impact factor: 79.321

9.  Acute Kidney Injury Presenting as Hepatorenal Syndrome in the Setting of Glecaprevir/Pibrentasvir Treatment for Hepatitis C.

Authors:  Kush Fansiwala; Jason Saltiel; Michael Poles
Journal:  ACG Case Rep J       Date:  2021-05-12
View more
  2 in total

1.  Advances in Parameter Estimation and Learning from Data for Mathematical Models of Hepatitis C Viral Kinetics.

Authors:  Vladimir Reinharz; Alexander Churkin; Harel Dahari; Danny Barash
Journal:  Mathematics (Basel)       Date:  2022-06-19

2.  Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration.

Authors:  Ashish Goyal; Alex Churkin; Danny Barash; Scott J Cotler; Amir Shlomai; Ohad Etzion; Harel Dahari
Journal:  Open Forum Infect Dis       Date:  2022-03-22       Impact factor: 4.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.